Press Releases Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
7.04 ^USD	-0.56%		+10.52%	-36.06%

02/05	Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M	MT
02/05	Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights	03/05	GL
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024	26/04	GL
Relay Therapeutics to Participate in Upcoming Investor Conferences	12/04	GL
Relay Therapeutics to Participate in Three Upcoming Investor Conferences	27/02	GL
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	23/02	GL
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024	16/02	GL
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024	16/02	AQ
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	02/02	GL
Relay Therapeutics Announces $30 Million Private Placement Financing	08/01	GL
Relay Therapeutics Announces $30 Million Private Placement Financing	08/01	AQ
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	03/01	GL
X-Chem Announces Achievement of Collaboration Milestone	06/12	AQ
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference	08/11	GL
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights	03/11	GL
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023	27/23/27	GL
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors	13/23/13	GL
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors	13/23/13	AQ
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	19/23/19	GL
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights	09/23/09	GL
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023	02/23/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Press Releases

Filters